Table 1 Demographics and baseline clinical characteristics of the patients and clinical samples
Patients | Number (%) (n = 85) | Median [IQR] |
Age (years) | 64 [54–69] | |
Male | 62 (73) | |
Co-morbid conditions | ||
Heart transplant | 10 (12) | |
Lung transplant | 10 (12) | |
COPD | 14 (16) | |
Active chemotherapy for cancer* | 6 (7) | |
AIDS | 5 (6) | |
Chronic dialysis | 3 (4) | |
Clinical samples | Number (%) (n = 95) | Median [IQR] |
Pneumonia | ||
Ventilator-associated | 71 (75) | |
Ventilated hospital-acquired | 24 (25) | |
Severity of disease | ||
Days in intensive care | 5.6 [3.5–14] | |
SAPS II score | 59 [36–72] | |
Days of mechanical ventilation | 5.5 [3.4–11] | |
Relapse of pneumonia | 24 (25) | |
Deaths | 30 (32) | |
Laboratory | ||
ESBL carrier | 23 (24) | |
MRSA carrier | 1 (1) | |
Antibiotics in the 7 days before the episode of pneumonia** | 41 (43) | |
Cefotaxime | 11 (12) | |
Piperacillin-tazobactam | 7 (7) | |
Amikacin | 7 (7) | |
Cefepime | 6 (6) | |
Metronidazole | 5 (5) | |
Sampling | ||
Bronchoalveolar lavage | 72 (76) | |
Plugged telescoping catheter | 23 (24) | |
Turnaround time of Unyvero HPN (hours) | 4.6 [4.4–5] | |
Lysis | 0.5 [0.5–0.5 | |
Waiting time | 0.1 [0.1–0.4] | |
Analysis | 3.8 [3.8–3.8] | |